$157.68
1.53% yesterday
NYSE, Jul 15, 10:10 pm CET
ISIN
US46266C1053
Symbol
IQV

IQVIA Stock price

$157.68
-1.57 0.99% 1M
-38.42 19.59% 6M
-38.83 19.76% YTD
-68.21 30.20% 1Y
-61.40 28.03% 3Y
+5.31 3.48% 5Y
+81.75 107.67% 10Y
+115.57 274.45% 20Y
NYSE, Closing price Tue, Jul 15 2025
-2.45 1.53%
ISIN
US46266C1053
Symbol
IQV
Sector

Key metrics

Basic
Market capitalization
$27.7b
Enterprise Value
$40.2b
Net debt
$12.5b
Cash
$1.9b
Shares outstanding
174.1m
Valuation (TTM | estimate)
P/E
21.3 | 13.4
P/S
1.8 | 1.7
EV/Sales
2.6 | 2.5
EV/FCF
18.6
P/B
4.6
Financial Health
Equity Ratio
22.6%
Return on Equity
22.6%
ROCE
11.3%
ROIC
9.5%
Debt/Equity
2.4
Financials (TTM | estimate)
Revenue
$15.5b | $16.2b
EBITDA
$3.4b | $3.8b
EBIT
$2.3b | $3.1b
Net Income
$1.3b | $2.1b
Free Cash Flow
$2.2b
Growth (TTM | estimate)
Revenue
2.8% | 5.3%
EBITDA
4.9% | 13.1%
EBIT
8.5% | 37.6%
Net Income
-1.7% | 51.6%
Free Cash Flow
33.2%
Margin (TTM | estimate)
Gross
34.7%
EBITDA
21.9% | 23.6%
EBIT
14.7%
Net
8.6% | 12.8%
Free Cash Flow
14.0%
More
EPS
$7.5
FCF per Share
$12.4
Short interest
6.3%
Employees
88k
Rev per Employee
$180.0k
Show more

Is IQVIA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

IQVIA Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a IQVIA forecast:

20x Buy
69%
9x Hold
31%

Analyst Opinions

29 Analysts have issued a IQVIA forecast:

Buy
69%
Hold
31%

Financial data from IQVIA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
15,497 15,497
3% 3%
100%
- Direct Costs 10,117 10,117
3% 3%
65%
5,380 5,380
2% 2%
35%
- Selling and Administrative Expenses 1,992 1,992
3% 3%
13%
- Research and Development Expense - -
-
-
3,388 3,388
5% 5%
22%
- Depreciation and Amortization 1,115 1,115
2% 2%
7%
EBIT (Operating Income) EBIT 2,273 2,273
9% 9%
15%
Net Profit 1,334 1,334
2% 2%
9%

In millions USD.

Don't miss a Thing! We will send you all news about IQVIA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IQVIA Stock News

Neutral
Business Wire
15 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a confe...
Neutral
Investors Business Daily
19 days ago
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work?
Neutral
Business Wire
30 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the “Best Mobile App for Patient Engagement” in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space...
More IQVIA News

Company Profile

Provides biopharmaceutical development services and commercial outsourcing services

Head office United States
CEO Ari Bousbib
Employees 88,000
Founded 1950
Website ir.iqvia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today